Glioblastoma - Pipeline Insight, 2022
![](/report_cover/8047/glioblastoma-pipeline-insight-2021_en.gif)
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Glioblastoma - Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Glioblastoma: Overview
Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes that support nerve cells.It can occur at any age, but tends to occur more often in older adults. It can cause worsening headaches, nausea, vomiting and seizures.Glioblastoma, also known as glioblastoma multiforme. Glioma is a type of tumor that occurs in the brain and spinal cord. Gliomas begin in the gluey supportive cells (glial cells) that surround nerve cells and help them function. Three types of glial cells can produce tumors. Gliomas are classified according to the type of glial cell involved in the tumor, as well as the tumor's genetic features, which can help predict how the tumor will behave over time and the treatments most likely to work. The symptoms of glioma vary by tumor type as well as the tumor's size, location and rate of growth. Common signs and symptoms of gliomas include: headache, nausea or vomiting, confusion or a decline in brain function, memory loss, personality changes or irritability and difficulty with balance. Like most primary brain tumors, the exact cause of gliomas is not known. Treatments may slow progression of the cancer and reduce signs and symptoms.
'Glioblastoma - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glioblastoma pipeline landscape is provided which includes the disease overview and Glioblastoma treatment guidelines. The assessment part of the report embraces, in depth Glioblastoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Glioblastoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glioblastoma Emerging Drugs
Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Fibromun has also shown promising activity in orthotopic mouse models of glioblastoma and in high-grade glioma patients (studies performed in collaboration with the University Hospital Zurich). On the basis of the promising results observed in a phase I/II monotherapy study in patients with recurrent glioma, two clinical studies with registration potential have recently been started in newly diagnosed and in recurrent glioblastoma patients, respectively.
Further product details are provided in the report……..
Glioblastoma: Therapeutic Assessment
This segment of the report provides insights about the different Glioblastoma drugs segregated based on following parameters that define the scope of the report, such as:
Glioblastoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postoperative Pain therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glioblastoma drugs.
Glioblastoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Glioblastoma - Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Glioblastoma: Overview
Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes that support nerve cells.It can occur at any age, but tends to occur more often in older adults. It can cause worsening headaches, nausea, vomiting and seizures.Glioblastoma, also known as glioblastoma multiforme. Glioma is a type of tumor that occurs in the brain and spinal cord. Gliomas begin in the gluey supportive cells (glial cells) that surround nerve cells and help them function. Three types of glial cells can produce tumors. Gliomas are classified according to the type of glial cell involved in the tumor, as well as the tumor's genetic features, which can help predict how the tumor will behave over time and the treatments most likely to work. The symptoms of glioma vary by tumor type as well as the tumor's size, location and rate of growth. Common signs and symptoms of gliomas include: headache, nausea or vomiting, confusion or a decline in brain function, memory loss, personality changes or irritability and difficulty with balance. Like most primary brain tumors, the exact cause of gliomas is not known. Treatments may slow progression of the cancer and reduce signs and symptoms.
'Glioblastoma - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glioblastoma pipeline landscape is provided which includes the disease overview and Glioblastoma treatment guidelines. The assessment part of the report embraces, in depth Glioblastoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Glioblastoma R&D. The therapies under development are focused on novel approaches to treat/improve Glioblastoma.
This segment of the Glioblastoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glioblastoma Emerging Drugs
- TVB2640:Ascletis Pharma
- Trabedersen: Oncotelic Therapeutics
- Selinexor: Karyopharm Therapeutics
- Onfekafuspalfa: Philogen
Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Fibromun has also shown promising activity in orthotopic mouse models of glioblastoma and in high-grade glioma patients (studies performed in collaboration with the University Hospital Zurich). On the basis of the promising results observed in a phase I/II monotherapy study in patients with recurrent glioma, two clinical studies with registration potential have recently been started in newly diagnosed and in recurrent glioblastoma patients, respectively.
- AZD1390: AstraZeneca
- YTX7739: Yumanity Therapeutics
Further product details are provided in the report……..
Glioblastoma: Therapeutic Assessment
This segment of the report provides insights about the different Glioblastoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Glioblastoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Glioblastoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postoperative Pain therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glioblastoma drugs.
Glioblastoma Report Insights
- Glioblastoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Glioblastoma drugs?
- How many Glioblastoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glioblastoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glioblastoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glioblastoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Array Biopharma
- AstraZeneca
- Doule bond Pharmaceuticals
- Philogen
- Immatics N.V
- BioNTech
- InovioPharma
- Noxxon Pharma
- Celgene Corporation
- Karyo Pharma
- Neugate Theranostics
- Novartis
- Orphelia Pharma
- Merck
- Acerta Pharma
- Genenta Science
- CNS Pharmaceutical
- Pfizer
- Roche
- Oncotelic Therapeutics
- Autotelic Therapeutics
- ACADIA Pharmaceuticals
- Mayo Clinic
- Cytogel
- Xgene Pharmaceutical
- Ascletis
- 3-V Biosciences
- Yumanity Therapeutics
- Onfekafuspalfa
- PLX3397
- APVAC1
- INO5401
- Olaptesed pegol
- Selinexor
- L19TNF
- H1PV
- NG101m
- ACP196
- Temferon
- Berubicin Hydrochloride
- VXM01
- Avelumab
- Trabedersen
- TVB2640
- AZD1390
- YTX7739
- WP1122
Introduction
Executive Summary
Glioblastoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Glioblastoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Trabedersen: Oncotelic Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Selinexor: KaryoPharm Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AZD1390: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
YTX7739: Yumanity Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Glioblastoma -Key Companies
Glioblastoma -Key Products
Glioblastoma - Unmet Needs
Glioblastoma - Market Drivers and Barriers
Glioblastoma- Future Perspectives and Conclusion
Glioblastoma -Analyst Views
Glioblastoma -Key Companies
Appendix
Executive Summary
Glioblastoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Glioblastoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Trabedersen: Oncotelic Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Selinexor: KaryoPharm Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AZD1390: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
YTX7739: Yumanity Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Glioblastoma -Key Companies
Glioblastoma -Key Products
Glioblastoma - Unmet Needs
Glioblastoma - Market Drivers and Barriers
Glioblastoma- Future Perspectives and Conclusion
Glioblastoma -Analyst Views
Glioblastoma -Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Glioblastoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Glioblastoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Glioblastoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Glioblastoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products